newsfilter
← Latest News
ACCESS Newswire·

BioAdaptives Acquisition Target Xycota Biosciences Launches Free PTSD Tactical & Support Hub for Veterans and First Responders Alongside At-Home Psilocybin Research

  • BioAdaptives Inc. (OTCID:BDPT) & Xycota Biosciences launched a free, zero-login PTSD Community & Resource Hub at xycota.com/ptsd today to support veterans, first responders, & families.
  • The digital hub offers immediate breathing tools, sensory grounding exercises, & a confidential support matcher without requiring account creation or cloud data storage.
  • Xycota is preparing a Canadian clinical trial application with KGK Science to test the XYCO-02 candidate, a low-dose oral psilocybin designed for at-home use to engage the BDNF/TrkB repair pathway.
  • BioAdaptives signed a definitive agreement to acquire Xycota, maintaining separate biotech & nutraceutical operations with conditional funding for a proposed spin-off.
  • The acquisition deal enforces a 12-month founder lock-up, daily note resale limits, & milestone-gated R&D financing tranches to protect shareholders.
  • The hub's guidance comes from Lt. Col. Elton Johnson Jr. (Ret.) & Dr. Marvin S. Hausman, who emphasize accessible tools alongside rigorous research into sub-perceptual psilocybin effects.
  • Preclinical data from a 2026 rat study suggests low-dose psilocybin may restore memory via TrkB pathways, though no human PTSD trials are currently recruiting.
  • Regulatory disclosures state XYCO-01 & XYCO-02 remain unapproved investigational candidates involving Schedule I substances with no safety or efficacy claims.
  • The transaction remains subject to closing conditions detailed in BioAdaptives' November 4, 2026 Form 8-K filing.
Company
BioAdaptives, Inc.
Keywords
Healthcare & Pharmaceutical, Company Update